NBIX
NBIX clinical trials: NEUROCRINE BIOSCIENCES INC
Every trial on ClinicalTrials.gov where NEUROCRINE BIOSCIENCES INC is the lead sponsor or a listed collaborator, the trials it leads first, each labelled Lead or Collaborator. Phase, status and dates as registered.
- 114
- Trials linked
- 107
- As lead sponsor
- 7
- As collaborator
- 0
- Primary completions as lead sponsor, next 90 days
NBIX on the catalyst calendar · NBIX registry changes
- Primary completion Feb 2027Sponsor estimatePhase 2NCT07365462Efficacy, Safety, and Tolerability of NBI-1065890 Versus Placebo in Adults With Tardive DyskinesiaNeurocrine Biosciences · Tardive DyskinesiaRecruitingNBIXLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Jul 2027Sponsor estimatePhase 3NCT06963021NBI-1065845-MDD3026: Study to Assess the Efficacy and Safety of Osavampator as an Adjunctive Treatment in Participants With Major...Neurocrine Biosciences · Major Depressive DisorderRecruitingNBIXLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Jul 2027Sponsor estimatePhase 3NCT06911112NBI-1065845-MDD3025: Study to Assess the Efficacy and Safety of Osavampator as an Adjunctive Treatment in Participants With Major...Neurocrine Biosciences · Major Depressive DisorderRecruitingNBIXLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Jul 2027Sponsor estimatePhase 3NCT06786624Study to Assess the Efficacy and Safety of Osavampator as an Adjunctive Treatment in Participants With Major Depressive Disorder (MDD)Neurocrine Biosciences · Major Depressive DisorderRecruitingNBIXLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Nov 12, 2025ActualPhase 2NCT05226780Extension Study to Evaluate How Safe and Tolerable NBI-921352 is as an Adjunctive Therapy for Participants With SCN8A-DEENeurocrine Biosciences · SCN8A Developmental and Epileptic Encephalopathy SyndromeTerminatedNBIXLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Nov 2028Sponsor estimatePhase 1NCT07934303Study of NBIB-223 Gene Therapy in Friedreich's Ataxia (FACET)Neurocrine Biosciences · Friedreich's AtaxiaNot yet recruitingNBIXLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Nov 5, 2025ActualPhase 3NCT04400331Open-Label Rollover Study for Continuing Valbenazine Administration for the Treatment of Chorea Associated With Huntington DiseaseNeurocrine Biosciences · Chorea, HuntingtonTerminatedNBIXLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion May 2029Sponsor estimatePhase 3NCT06966401Long-Term Study to Assess the Safety and Tolerability of NBI-1065845 as an Adjunctive Treatment in Participants With Major Depressive...Neurocrine Biosciences · Major Depressive DisorderRecruitingNBIXLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Jul 2028Sponsor estimatePhase 3NCT07196501A Study to Evaluate the Maintenance Effect of Osavampator as an Adjunctive Treatment in Participants With Major Depressive Disorder (MDD)Neurocrine Biosciences · Major Depressive DisorderRecruitingNBIXLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Feb 2028Sponsor estimatePhase 2NCT07288320An Assessment of Efficacy, Safety, and Pharmacokinetics of NBI-1117568 in Adults With Bipolar I Disorder With Current ManiaNeurocrine Biosciences · Bipolar I DisorderRecruitingNBIXLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Mar 16, 2028Sponsor estimatePhase 2NCT07850739Efficacy, Safety, Tolerability, and Pharmacokinetics of NBIP-01435 in Adult Participants With Classic Congenital Adrenal Hyperplasia (CAH)Neurocrine Biosciences · Congenital Adrenal HyperplasiaNot yet recruitingNBIXLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Jul 2029Sponsor estimatePhase 3NCT07227818Efficacy of NBI-1117568 in Preventing Relapse in Adults With SchizophreniaNeurocrine Biosciences · SchizophreniaRecruitingNBIXLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Dec 2031Sponsor estimatePhase 3NCT07114874NBI-1117568-SCZ3032: Long-Term Evaluation of NBI-1117568 in Adults With SchizophreniaNeurocrine Biosciences · SchizophreniaRecruitingNBIXLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Nov 2027Sponsor estimatePhase 3NCT07105098NBI-1117568-SCZ3030: Evaluation of NBI-1117568 in Inpatient Adults With SchizophreniaNeurocrine Biosciences · SchizophreniaRecruitingNBIXLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion May 2028Sponsor estimatePhase 2NCT07832383Evaluation of NBI-1117567 in Participants With Mild to Moderate Alzheimer's Disease (AD) Taking a Background Acetylcholinesterase InhibitorNeurocrine Biosciences · Alzheimer's DiseaseNot yet recruitingNBIXLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Jun 2028Sponsor estimatePhase 4NCT07105111A Study to Evaluate the Effectiveness of Valbenazine in Adult Participants With Tardive Dyskinesia (TD) Who Remain Symptomatic While...Neurocrine Biosciences · SchizophreniaRecruitingNBIXLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Mar 2028Sponsor estimatePhase 2NCT07536269Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Crinecerfont in Participants With Classic Congenital Adrenal Hyperplasia...Neurocrine Switzerland GmbH · Congenital Adrenal HyperplasiaRecruitingNBIXLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Oct 18, 2023ActualPhase 2NCT05222152Chronocort Versus Plenadren Replacement Therapy in Adults With Adrenal InsufficiencyNeurocrine UK Limited · Primary Adrenal InsufficiencyCompletedNBIXLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Feb 2, 2024ActualPhase 3NCT05063994Comparison of Chronocort Versus Standard Hydrocortisone Replacement Therapy in Participants Aged 16 Years and Over With Congenital...Neurocrine UK Limited · Congenital Adrenal HyperplasiaCompletedNBIXLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Oct 17, 2018ActualPhase 3NCT03532022Open-label Comparison of Chronocort® Versus Standard Glucocorticoid Replacement TherapyNeurocrine UK Limited · Congenital Adrenal HyperplasiaWithdrawnNBIXLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Apr 20, 2018ActualPhase 1NCT03343327A Study of Chronocort® Versus Cortef ® in Healthy Adult Male SubjectsNeurocrine UK Limited · Adrenal InsufficiencyCompletedNBIXLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Jul 13, 2018ActualPhase 1NCT03311932A Study of Infacort® Versus Cortef® in Healthy Adult Male and Female SubjectsNeurocrine UK Limited · Adrenal InsufficiencyCompletedNBIXLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Jul 26, 2017ActualPhase 1NCT03178214Bioavailability of Infacort When Administered Onto Food Compared to Direct Oral AdministrationNeurocrine UK Limited · Adrenal InsufficiencyCompletedNBIXLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Jul 13, 2022ActualPhase 3NCT03062280A Study of the Efficacy, Safety and Tolerability of Chronocort in Treating CAHNeurocrine UK Limited · Congenital Adrenal HyperplasiaCompletedNBIXLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Apr 2012ActualPhase 1NCT03051893A Two-part, Study to Compare the Pharmacokinetics and Dose Proportionality of up to 6 Chronocort FormulationsNeurocrine UK Limited · Adrenal InsufficiencyCompletedNBIXLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
Enrollment, interventions and the start and completion dates are locked on 25 rows here. Included with TrialScanner ($9.99 a month) and Signal8 Pro.
Unlock with TrialScannerShowing the first 25 trials. There are 89 more in this window; the full list is part of TrialScanner.
Unlock with TrialScanner